{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:45:57Z","timestamp":1791229557858,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.esmoop.2024.103643","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T18:10:01Z","timestamp":1722449401000},"page":"103643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"G.","family":"Curigliano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Keam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rutten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Glaspy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.J.","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4746-1168","authenticated-orcid":false,"given":"N.S.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ising","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hassounah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9776-479X","authenticated-orcid":false,"given":"J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Leyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5022-3323","authenticated-orcid":false,"given":"X.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Burks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9945-6862","authenticated-orcid":false,"given":"A.","family":"Chaudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2216-9750","authenticated-orcid":false,"given":"J.","family":"Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4412-7842","authenticated-orcid":false,"given":"E.Garralda","family":"Cabanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2024.103643_bib1","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.3389\/fimmu.2018.02379","article-title":"Pattern recognition receptors and the host cell death molecular machinery","volume":"9","author":"Amarante-Mendes","year":"2018","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103643_bib2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.esmoop.2024.103643_bib3","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fphar.2017.00304","article-title":"Anti-tumor activity of toll-like receptor 7 agonists","volume":"8","author":"Chi","year":"2017","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103643_bib4","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1189\/jlb.1012501","article-title":"TLR agonists: our best frenemy in cancer immunotherapy","volume":"93","author":"Kaczanowska","year":"2013","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.esmoop.2024.103643_bib5","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1073\/pnas.0400937101","article-title":"Recognition of single-stranded RNA viruses by toll-like receptor 7","volume":"101","author":"Lund","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103643_bib6","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.4161\/21645515.2014.979640","article-title":"Mechanisms and pathways of innate immune activation and regulation in health and cancer","volume":"10","author":"Cui","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103643_bib7","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3390\/ijms18020404","article-title":"Promising targets for cancer immunotherapy: TLRs, RLRs, and STING-mediated innate immune pathways","volume":"18","author":"Li","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103643_bib8","first-page":"261","article-title":"Recent advances in cancer immunotherapy: modulation of tumor microenvironment by Toll-like receptor ligands","volume":"12","author":"Rostamizadeh","year":"2022","journal-title":"BioImpacts"},{"issue":"suppl 13","key":"10.1016\/j.esmoop.2024.103643_bib9","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.1158\/1538-7445.AM2019-4128","article-title":"Abstract 4128: Identification and characterization of LHC165, a TLR7 agonist designed for localized intratumoral therapies","volume":"79","author":"Deane","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103643_bib10","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1200\/JCO.2010.32.8971","article-title":"Randomized phase III trial of paclitaxel\/carboplatin with or without PF-3512676 (toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer","volume":"29","author":"Hirsh","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103643_bib11","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/annonc\/mdr030","article-title":"A\u00a0phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer","volume":"23","author":"Manegold","year":"2012","journal-title":"Ann Oncol"},{"issue":"27-28","key":"10.1016\/j.esmoop.2024.103643_bib12","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1016\/j.vaccine.2004.03.032","article-title":"Aluminium adjuvants - in retrospect and prospect","volume":"22","author":"Lindblad","year":"2004","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103643_bib13","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrclinonc.2015.105","article-title":"Inflammation and cancer: advances and new agents","volume":"12","author":"Crusz","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103643_bib14","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.intimp.2017.03.015","article-title":"Primary and acquired resistance to PD-1\/PD-L1 blockade in cancer treatment","volume":"46","author":"Wang","year":"2017","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103643_bib15","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.7150\/thno.58390","article-title":"Turning cold tumors into hot tumors by improving T-cell infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103643_bib16","article-title":"A\u00a0first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti\u2013PD-1 antibody, in patients with advanced solid tumors","volume":"8","author":"Naing","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.esmoop.2024.103643_bib17","first-page":"2620","volume":"38","author":"Capdevila","year":"2020"},{"issue":"18","key":"10.1016\/j.esmoop.2024.103643_bib18","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93397","article-title":"Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer","volume":"2","author":"Sato-Kaneko","year":"2017","journal-title":"JCI Insight"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103643_bib19","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.4049\/jimmunol.1401160","article-title":"Effective innate and adaptive antimelanoma immunity through localized TLR7\/8 activation","volume":"193","author":"Singh","year":"2014","journal-title":"J.\u00a0Immunol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103643_bib21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2024.103643_bib22","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0","year":"2017"},{"key":"10.1016\/j.esmoop.2024.103643_bib23","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103643_bib24","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1158\/2159-8290.CD-18-0280","article-title":"Sd-101 in combination with pembrolizumab in advanced melanoma: results of a phase Ib, multicenter study","volume":"8","author":"Ribas","year":"2018","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103643_bib25","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1158\/1078-0432.CCR-21-1411","article-title":"Intralesional SD-101 in combination with pembrolizumab in anti\u2013PD-1 treatment-na\u00efve head and neck squamous cell carcinoma: results from a multicenter, phase II trial","volume":"28","author":"Cohen","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"suppl 13","key":"10.1016\/j.esmoop.2024.103643_bib26","article-title":"Abstract CT091: safety and pharmacodynamic activity of MEDI9197, a TLR 7\/8 agonist, administered intratumorally in subjects with solid tumors","volume":"77","author":"Gupta","year":"2017","journal-title":"Cancer Res"},{"issue":"suppl 13","key":"10.1016\/j.esmoop.2024.103643_bib27","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1538-7445.AM2019-4062","article-title":"Abstract 4062: activation of innate and adaptive immunity using intratumoral tilsotolimod (IMO-2125) as monotherapy in patients with refractory solid tumors: a phase Ib study (ILLUMINATE-101)","volume":"79","author":"Babiker","year":"2019","journal-title":"Cancer Res"},{"issue":"23","key":"10.1016\/j.esmoop.2024.103643_bib28","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1158\/1078-0432.CCR-22-2427","article-title":"Intratumoral therapy to make a \u201ccold\u201d tumor \u201chot\u201d: the jury is still out","volume":"28","author":"Punekar","year":"2022","journal-title":"Clin. Cancer Res"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:06:37Z","timestamp":1737331597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924014121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2059702924014121"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103643","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103643","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103643"}}